<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000946.v1.p1" parentStudy="phs000946.v1.p1" createDate="2015-07-01" modDate="2016-10-11">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Edwin K. Silverman</td><td>Brigham and Women&#39;s Hospital 			Boston, MA   USA</td></tr>
		<tr><td>Funding Source</td><td>R01HL113264</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>R01HL089856</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NHLBI TOPMed: Boston Early-Onset COPD Study in the TOPMed Program</StudyNameEntrez>
	<StudyNameReportPage>NHLBI TOPMed: Boston Early-Onset COPD Study in the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) Program</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Pedigree Whole Genome Sequencing</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project collected a set of extended pedigrees ascertained through subjects with severe, early-onset COPD. This study has enrolled subjects with severe COPD (forced expiratory volume in one second (FEV1) &#60; 40% predicted) at an early age (&#60; 53 years) without alpha-1 antitrypsin deficiency (a known Mendelian risk factor for COPD). Extended pedigrees are enrolled, primarily in New England, although some more geographically distant subjects have been included. This study has been used for epidemiological studies, familial aggregation analysis, linkage analysis, and candidate gene association analysis. Approximately 80 of the severe, early-onset COPD probands will undergo whole genome sequencing in this project with sequencing data available through dbGaP.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>COPD Probands:</b><br/> <b>Inclusion Criteria</b><br/> Age at Enrollment: &#60; 53 years<br/> Pre-bronchodilator FEV1 &#8804; 40% predicted)<br/> Physician-diagnosed COPD<br/> <b>Exclusion Criteria</b><br/> Severe alpha-1 antitrypsin deficiency<br/> Concomitant respiratory disorder other than asthma or COPD (such as, but not limited to, diffuse bronchiectasis, cystic fibrosis, or interstitial lung disease)<br/> Lung surgery with removal of a lobe or more (including lung volume reduction surgery or lung transplantation) unless preoperative pulmonary function tests are available<br/> </p> <p><b>Relatives of EOCOPD Probands</b><br/> <b>Inclusion Criteria</b><br/> Age at enrollment: 10 years or greater<br/> First or second-degree relative of an EOCOPD proband, or first-degree relative of another affected pedigree member<br/> <b>Exclusion Criteria</b><br/> Severe alpha-1 antitrypsin deficiency<br/> Concomitant respiratory disorder other than asthma or COPD (such as, but not limited to, diffuse bronchiectasis, cystic fibrosis, or interstitial lung disease)<br/> Lung surgery with removal of a lobe or more (including lung volume reduction surgery or lung transplantation) unless preoperative pulmonary function tests are available<br/> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="9620904"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11112130"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Chronic Obstructive Pulmonary Disease"/>
		<Disease vocab_source="MESH" vocab_term="Emphysema"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Edwin K. Silverman</AttName>
			<Institution>Brigham and Women&#39;s Hospital 			Boston, MA   USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01HL113264</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01HL089856</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Boston COPD" url="http://bostoncopd.org/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>The Boston Early-Onset COPD was started in 1994 in an effort to find genetic determinants of COPD other than alpha-1 antitrypsin deficiency. This study has been funded by a series of grants from the NHLBI, most recently by R01 HL113264 (MPIs: Edwin K. Silverman and Michael H. Cho) and by an administrative supplement to R01 HL089856 (PI: Edwin K. Silverman).</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CS-RD" longName="Disease-Specific (COPD and Smoking, RD)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000946.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000946.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000946.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="999">
        <ConsentName>Exchange Area</ConsentName>
        <ConsentAbbrev>EA</ConsentAbbrev>
        <UseLimitation>Use by NHLBI WGS study investigators only
There is one consent group for this study: DS-CS-RD, Disease-Specific (COPD and Smoking, RD).
Use of the data must be related to COPD and Smoking and related disorders.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd006969.1" type="protocol" createDate="2016-10-05" modDate="2016-10-11" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd006969.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000946.v1.p1&amp;phd=6969">
      <OrigName>TOPMed_document.txt</OrigName>
      <DisplayName>TOPMed Whole Genome Sequencing Project</DisplayName>
      <Description>TOPMed Whole Genome Sequencing Project</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
  </Documents>



</Study>

</Studies>

</GaPExchange>
